Differences

This shows you the differences between two versions of the page.

--- jc [2024/11/16 21:11] – admin
+++ jc [2026/03/31 14:20] (current) – admin
@@ Line 12: / Line 12: @@
       * **Finding**: In patients with acute myocardial infarction and anemia, a liberal transfusion strategy did not significantly reduce the risk of recurrent myocardial infarction or death at 30 days.
   * CCM
+    * [[https://dx.doi.org/10.1056/NEJMoa2516567 | HI-PEITHO for intermediate risk PE]]
+    * [[http://doi.org/10.1056/NEJMoa2502136 | No Art Line in Shock]]
     * [[https://doi.org/10.1056/NEJMoa2404245 | Pantoprazole for MV GI bleed ppx]]
       * **Finding**: reduces GIB, no mortality benefit
@@ Line 20: / Line 22: @@
       * **Finding**: Impella CP reduces mortality
       * **Significance**: First trial to show mortality benefit from MCS
+  * MV
+    * [[https://doi.org/10.1164/rccm.202503-0544OC | SBT respiratory mechanics to predict re-intubation]]
+      * in reintubation group, normalized compliance declined and inspiratory effort increased. in non-reintubated group, $C_{norm}$ and $E_{insp}$ unchanged throughout SBT
   * PULM
+    * [[https://doi.org/10.1056/NEJMoa2507100 | Steroids in Non-Severe CAP]]
+    * [[https://doi.org/10.1056/NEJMoa2411664 | brensocatib for bronchiectasis]]
     * [[ https://www.nejm.org/doi/full/10.1056/NEJMoa2406673 | Depemokimab]]
     * [[https://www.nejm.org/doi/full/10.1056/NEJMoa2409712 | Inebilizumab for Treatment of IgG4-Related Disease]]

ewrobbins.com